Core Framework & Diagram The Future of Cancer Vaccines
7 月 24, 20261 Min Read The Future of Immunotherapy
7 月 24, 2026Cancer vaccines are no longer only about prevention — they're becoming weapons of treatment
—— From HPV vaccines to individualized mRNA tumor vaccines: the three evolutionary trajectories of cancer vaccines.
I. HPV vaccine: one of history's most successful cancer prevention tools
Human papillomavirus (HPV) infection is the leading cause of cervical cancer — over ninety-nine percent of cervical cancer tissue can detect HPV. The high-risk HPV types 16 and 18 cause approximately seventy percent of cervical cancers. HPV vaccines (Gardasil series, Cervarix, etc.), by activating immune memory against HPV viral proteins, enable vaccinated individuals to rapidly clear the virus when they contact it, preventing infection from developing into persistent infection, thereby blocking cervical cancer's occurrence. This is a milestone in cancer prevention history: one vaccine that can prevent one cancer. After Australia promoted HPV vaccines nationally, cervical cancer incidence dramatically declined — Australia is expected to reach the cervical cancer elimination target (annual incidence below four per 100,000) before 2028, which will be the first cancer eliminated through vaccination in history.
Special note for Asian readers: HPV vaccine coverage rates in Asia remain relatively low globally. China, Malaysia, and other countries have included HPV vaccines in national vaccination programs, but improving coverage rates remains an important public health task. For females aged nine to twenty-six (some guidelines extend to forty-five), and males aged nine to twenty-six (HPV is also associated with anal cancer and oropharyngeal cancer in males), HPV vaccine is one of the strongest evidence cancer prevention tools.
|
HPV vaccine is the first vaccine that can prevent cancer, and the most direct victory of the immune system in cancer prevention. It proves a principle: intervening before carcinogenic factors are established is orders of magnitude more efficient than treating after cancer has occurred. |
2. Sipuleucel-T: therapeutic vaccine's historic first
In 2010, FDA approved Sipuleucel-T (brand name Provenge) for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer — the world's first approved therapeutic cancer vaccine. Sipuleucel-T's preparation method embodies the basic logic of therapeutic vaccines: from patients' blood, extracting dendritic cells (APCs), incubating them in vitro with a fusion protein (fusion of prostatic acid phosphatase PAP and GM-CSF), activating dendritic cells to carry tumor-associated antigens, then reinfusing to patients. These activated dendritic cells, in patients, activate prostate cancer-specific T cells to attack prostate tumors. Clinical trials showed Sipuleucel-T extended metastatic prostate cancer patients' median overall survival by approximately four point one months and reduced death risk by twenty-two percent.
Sipuleucel-T exited the market in 2022 (manufacturer commercial decision, not safety issues), but its historical significance is undiminished: it was the first clinical proof that 'therapeutic cancer vaccines can work,' paving the cognitive foundation for subsequent third-generation individualized vaccines.
3. mRNA individualized tumor vaccines: one of 2023's most important clinical breakthroughs
In 2023, Moderna and Merck's jointly developed mRNA-4157 released Phase 2 clinical trial data, shaking the entire tumor immunology world. mRNA-4157 is an individualized neoantigen vaccine: whole-exome sequencing of each patient's tumor tissue and normal tissue to find tumor-specific somatic mutations; AI algorithms screen the twenty to thirty-four neoantigen sequences most likely to be presented by the patient's HLA type and most likely to activate T cell responses; synthesize mRNA vaccines carrying at most thirty-four neoantigens, used combined with PD-1 inhibitor (Pembrolizumab/Keytruda).
In Phase 2 trial (KEYNOTE-942, targeting high-risk melanoma after surgical resection), compared to using Pembrolizumab alone, mRNA-4157 combined with Pembrolizumab: reduced tumor recurrence or death risk by forty-four percent (HR=0.56, p=0.003); three-year recurrence-free survival rate, combined group 74.8%, Pembrolizumab alone group 55.6%; distant metastasis or death risk reduced sixty-five percent. These numbers, in a high-risk melanoma adjuvant treatment context, have profound significance. BioNTech's mRNA cancer vaccine (BNT122, targeting pancreatic cancer) also released early data in 2023: of eight patients who received individualized mRNA vaccines after pancreatic cancer surgery, all eight produced tumor-specific T cell responses — and patients with strong T cell responses had no recurrence during follow-up, remarkable given pancreatic cancer's typically very high post-surgical recurrence rate (over eighty percent within eighteen months).
|
mRNA individualized tumor vaccines in 2023 achieved a leap from 'proof-of-concept' to 'Phase 2 data with real clinical significance.' 44% melanoma recurrence risk reduction isn't just a statistic — it's decades of accumulated research in this field finally bearing real fruit in the clinic. |
4. Why combining checkpoint inhibitors is key
In almost all promising therapeutic cancer vaccine clinical trial designs, there's a repeatedly appearing combination pattern: cancer vaccine + PD-1/PD-L1 inhibitor. This isn't coincidental — it has deep mechanistic logic. Cancer vaccine's mission: activate tumor-specific T cells (or B cells), letting the immune system know who to attack. PD-1 inhibitor's mission: remove the tumor microenvironment's blockade of already-activated T cells. Two's synergy: vaccine 'summons more soldiers,' PD-1 inhibitor 'removes the shackles on soldiers' — more soldiers, plus no shackles, naturally stronger anti-tumor effects. This combination represents an important strategy in cancer immunotherapy: combining 'increasing tumor-specific immune cell numbers' (vaccine) with 'removing immunosuppression' (checkpoint inhibitors), simultaneously solving 'not enough soldiers' and 'soldiers were locked up' problems.
5. Next frontier: predictive preventive intervention at high-recurrence-risk stages
Between 'prevention' and 'treatment,' there's a long-neglected but extremely valuable intervention window: pre-cancerous lesions or high-recurrence-risk periods. Directions being explored: colorectal adenoma preventive vaccines — colorectal adenoma (colon polyps) is a colorectal cancer precursor; research is exploring whether vaccines targeting colorectal adenoma-related antigens can reduce adenoma progression to cancer rates; multiple myeloma precursor lesions (MGUS/Smoldering Myeloma) — before progressing to active multiple myeloma, using vaccines to activate immune responses against myeloma cells, trying to maintain immune surveillance in the 'equilibrium' phase, delaying or even preventing progression to clinically treatable stages; BRCA1/2 mutation carriers — this high-risk population (lifetime breast or ovarian cancer risk up to seventy to eighty percent) is an ideal target group for preventive vaccines.
For the 2030 outlook: 2025–2027: mRNA-4157 or similar products, in melanoma adjuvant treatment, gaining FDA approval as the first approved mRNA cancer vaccine product; 2026–2028: pancreatic cancer, lung cancer, and other difficult solid tumors' individualized mRNA vaccines showing statistically significant survival improvement signals in combination treatment contexts; 2028–2030: cancer vaccine 'manufacturing time' compressed from current four to eight weeks to days within through AI-assisted neoantigen prediction and automated mRNA synthesis; costs decreasing from hundreds of thousands to tens of thousands of dollars.
Frequently Asked Questions